Egfr

Top News

• EGFR Non Small Cell Lung Cancer Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and ...

  GetNews 2026-10-07, 10:03

  (Albany, New York) - October 07, 2026: As per DelveInsight’s assessment, globally, EGFR Non Small Cell Lung...

• ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR ...

  Nasdaq Globe Newswire 2026-10-06, 15:32

  NEWTOWN SQUARE, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq:...

• ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC (Form 8-K) (ArriVent Biopharma Inc)

  Public Technologies 2026-10-06, 13:58

  ) ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20...

• New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program (Form 8-K) (Cullinan Therapeutics Inc)

  Public Technologies 2026-10-02, 12:00

  ) New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20...

• New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR

  Hastings Tribune 2026-10-02, 03:07

  In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free...

• New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion ...

  Nasdaq Globe Newswire 2026-10-01, 12:00

  In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free...

• HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors (Form 6-K) (HUTCHMED (China) Ltd)

  Public Technologies 2026-09-29, 11:51

  ) HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid...

• HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer (Form 6-K) (HUTCHMED (China) Ltd)

  Public Technologies 2026-09-29, 11:51

  ) HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer...

• HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated

  Hastings Tribune 2026-09-29, 07:20

  — Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET...

• HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

  The Daily Record - Dunn 2026-09-29, 01:58

  — Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET...

• HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients

  Hastings Tribune 2026-09-28, 06:17

  HONG KONG and SHANGHAI and FLORHAM...

• HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

  The Daily Record - Dunn 2026-09-28, 03:14

  First-in-class KRAS-payload leveraging synchronized EGFR inhibition ......

• Iterion Therapeutics Announces Promising Phase 1b Data for Tegavivint in Combination with Osimertinib in First-Line EGFR-Mutated Non-Small Cell Lung Cancer (Lumira Capital Investment Management Inc)

  Public Technologies 2026-09-22, 17:00

  ) Combination demonstrating 79% objective response rate (ORR), including complete responses (CRs) in 16% of...

• Presentation follows receipt of FDA Fast Track designation for BH-30643 for the treatment of advanced or metastatic EGFR C797S-positive NSCLC (Form 8-K) (Blossomhill Therapeutics Inc)

  Public Technologies 2026-09-15, 12:00

  ) Presentation follows receipt of FDA Fast Track designation for BH-30643 for the treatment of advanced or...

• Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy (Form 8-K) (Vera Therapeutics Inc)

  Public Technologies 2026-09-15, 12:00

  ) Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease...

• Ivonescimab-Chemo Versus Placebo-Chemo in EGFR-TKI–Resistant, EGFR-Mutated NSCLC (HARMONi): Updated Overall Survival Analysis (Summit Therapeutics Inc)

  Public Technologies 2026-09-15, 12:00

  ) The text version of this document is not available. You can access...

• Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer (Form 8-K) (Cullinan Therapeutics Inc)

  Public Technologies 2026-09-14, 12:00

  ) Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3...

• Johnson & Johnson’s RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer (Johnson & Johnson)

  Public Technologies 2026-09-14, 12:00

  ) Home/ Media Center/ Press releases / Innovative Medicine / Johnson & Johnson's RYBREVANT®...

• TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial (AstraZeneca Pharmaceuticals LP)

  Public Technologies 2026-09-14, 12:00

  ) PUBLISHED 14 September 2026 Longest survival data ever reported in a global Phase III trial in this setting...

• New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026 (Johnson & Johnson)

  Public Technologies 2026-09-11, 12:00

  ) Home/ Media Center/ Press releases / Innovative Medicine / New overall survival data and treatment...

• Amivantamab Lazertinib Forecast to Lead US EGFR NSCLC Therapy Revenue by 2036 as Post-TAGRISSO Competition Intensifies

  Nasdaq Globe Newswire 2026-07-14, 16:18

  Across the US, EU4, UK and Japan, opportunities center on...

• AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (Form 6-K) (AstraZeneca plc)

  Public Technologies 2026-07-14, 12:05

  ) FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule...

• AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (AstraZeneca plc)

  Public Technologies 2026-07-14, 08:05

  ) Complements AstraZeneca's leading portfolio of medicines targeting EGFR mutations Zegfrovy is approved in...